 Stem Cell Transplantation
"Stem Cell Transplantation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
| Descriptor ID |
D033581
|
| MeSH Number(s) |
E04.936.225.687
|
| Concept/Terms |
Stem Cell Transplantation- Stem Cell Transplantation
- Transplantation, Stem Cell
- Stem Cell Transplantations
- Transplantations, Stem Cell
|
Below are MeSH descriptors whose meaning is more general than "Stem Cell Transplantation".
Below are MeSH descriptors whose meaning is more specific than "Stem Cell Transplantation".
This graph shows the total number of publications written about "Stem Cell Transplantation" by people in UAMS Profiles by year, and whether "Stem Cell Transplantation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 3 | 3 | | 2021 | 0 | 2 | 2 | | 2020 | 4 | 5 | 9 | | 2019 | 3 | 2 | 5 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 1 | 2 | | 2016 | 4 | 1 | 5 | | 2015 | 1 | 1 | 2 | | 2014 | 3 | 1 | 4 | | 2013 | 7 | 3 | 10 | | 2012 | 2 | 1 | 3 | | 2011 | 1 | 3 | 4 | | 2010 | 0 | 3 | 3 | | 2009 | 1 | 0 | 1 | | 2008 | 3 | 2 | 5 | | 2007 | 2 | 3 | 5 | | 2006 | 3 | 1 | 4 | | 2005 | 2 | 1 | 3 | | 2004 | 2 | 4 | 6 | | 2003 | 2 | 4 | 6 | | 2002 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Stem Cell Transplantation" by people in Profiles over the past ten years.
-
Camilleri M, Bekris G, Sidhu G, Buck C, Elsden E, McCourt O, Horder J, Newrick F, Lecat C, Sive J, Papanikolaou X, Popat R, Lee L, Xu K, Kyriakou C, Rabin N, Yong K, Fisher A. The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study. Support Care Cancer. 2022 Sep; 30(9):7469-7479.
-
Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198.
-
Pawlyn C, Cairns D, Menzies T, Jones J, Jenner M, Cook G, Boyd K, Drayson M, Kaiser M, Owen R, Gregory W, Morgan G, Jackson G, Davies F. Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica. 2022 01 01; 107(1):231-242.
-
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Allotey D, Shafeek S, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Clinical Studies Group UNHO. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica. 2021 07 01; 106(7):1957-1967.
-
Mitma AA, Burgess MJ, van Rhee F. Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant. Transpl Infect Dis. 2021 Aug; 23(4):e13621.
-
Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood. 2020 11 26; 136(22):2491-2497.
-
Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol. 2021 02; 192(3):e73-e77.
-
Dimopoulos MA, Špicka I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020 12 01; 38(34):4030-4041.
-
Pina-Oviedo S, Thanendrarajan S. Meningeosis myelomatosis. Blood. 2020 09 17; 136(12):1466.
-
Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kortüm KM. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Cancer Med. 2020 08; 9(16):5819-5826.
-
Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, Jenner M, Cook G, Drayson M, Owen R, Gregory W, Morgan G, Jackson G, Kaiser M. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2021 05; 193(3):551-555.
-
Jagosky MH, Usmani SZ. Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig Rep. 2020 04; 15(2):62-71.
-
Shah V, Sherborne AL, Johnson DC, Ellis S, Price A, Chowdhury F, Kendall J, Jenner MW, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Davies FE, Cook G, Cairns DA, Houlston RS, Jackson G, Kaiser MF. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia. 2020 11; 34(11):3091-3096.
-
Song B, Cha Y, Ko S, Jeon J, Lee N, Seo H, Park KJ, Lee IH, Lopes C, Feitosa M, Luna MJ, Jung JH, Kim J, Hwang D, Cohen BM, Teicher MH, Leblanc P, Carter BS, Kordower JH, Bolshakov VY, Kong SW, Schweitzer JS, Kim KS. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
-
Boysen G, Shimoni A, Danylesko I, Varda-Bloom N, Nagler A. A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. Rapid Commun Mass Spectrom. 2019 Nov 15; 33(21):1635-1642.
-
Zhang LL, Shen KN, Zhang CL, Qiu Y, Miao HL, Feng J, Cao XX, Zhang L, Zhou DB, Li J. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. Leuk Res. 2019 11; 86:106226.
-
Einsele H, Rasche L, Topp MS, Martin Kortüm K, Duell J. The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. Bone Marrow Transplant. 2019 08; 54(Suppl 2):721-726.
-
Fraz MA, Warraich FH, Warraich SU, Tariq MJ, Warraich Z, Khan AY, Usman M, Ijaz A, Tenneti P, Mushtaq A, Akbar F, Shahid Z, Ali Z, Fazeel HM, Rodriguez C, Nasar A, McBride A, Anwer F. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Crit Rev Oncol Hematol. 2019 May; 137:18-26.
-
Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transpl Infect Dis. 2019 Apr; 21(2):e13052.
-
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 01 19; 393(10168):253-264.
-
Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr; 55:190-199.
-
Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, Langston A, Nooka AK. Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infect Control Hosp Epidemiol. 2017 06; 38(6):651-657.
-
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 09 29; 128(13):1735-44.
-
Ayyaswami V, Prabhu AV, Pugliano-Mauro M. Howard Green and the Accidental Birth of the Stem Cell Era. JAMA Dermatol. 2016 08 01; 152(8):912.
-
Damlaj M, Bartoo G, Cartin-Ceba R, Gijima D, Alkhateeb HB, Merten J, Hashmi S, Litzow M, Gastineau D, Hogan W, Patnaik MM. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016 Apr; 18(2):216-26.
-
Wilken R, Fung MA, Shi VY, Cheng MY, Patel F, Sultani H, Maverakis E. Cyclosporine-induced sebaceous hyperplasia in a hematopoetic stem cell transplant patient: delayed onset of a common adverse event. Dermatol Online J. 2016 Jan 15; 22(1).
-
Pandey T, Thomas S, Heller MT. Current Indications, Techniques, and Imaging Findings of Stem Cell Treatment and Bone Marrow Transplant. Radiol Clin North Am. 2016 Mar; 54(2):375-96.
-
Apewokin S, Goodwin JA, Lee JY, Erickson SW, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Stephens O, Coleman EA. Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation. Transpl Infect Dis. 2015 Aug; 17(4):566-73.
-
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
-
Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr; 21(4):738-45.
-
Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, van Duin M, Gregory WM, Davies FE, Brewer D, Hose D, Sonneveld P, Morgan GJ. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma. 2015 Mar; 56(3):594-601.
-
van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014 Jul 17; 124(3):328-33.
-
Fernández de Larrea C, Delforge M, Davies F, Bladé J. Response evaluation and monitoring of multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):33-42.
-
Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler-Fox M. Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. J Clin Apher. 2014 Oct; 29(5):251-5.
-
Eicher DM, Lonial S, Cavallo F, Palumbo A, Nair B, Waheed S, Hofmeister C, Rogers HJ. High-risk myeloma: when to transplant-or not. Semin Oncol. 2014 Feb; 41(1):e1-9.
-
Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ. The impact of response on bone-directed therapy in patients with multiple myeloma. Blood. 2013 Oct 24; 122(17):2974-7.
-
Morgan GJ. Transplants for the elderly in myeloma. Blood. 2013 Aug 22; 122(8):1332-4.
-
Kaneko Y, Dailey T, Weinbren NL, Rizzi J, Tamboli C, Allickson JG, Kuzmin-Nichols N, Sanberg PR, Eve DJ, Tajiri N, Borlongan CV. The battle of the sexes for stroke therapy: female- versus male-derived stem cells. CNS Neurol Disord Drug Targets. 2013 May 01; 12(3):405-412.
-
Selden NR, Al-Uzri A, Huhn SL, Koch TK, Sikora DM, Nguyen-Driver MD, Guillaume DJ, Koh JL, Gultekin SH, Anderson JC, Vogel H, Sutcliffe TL, Jacobs Y, Steiner RD. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013 Jun; 11(6):643-52.
-
Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013 Aug; 15(4):354-60.
-
Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013 Aug; 68(8):1872-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|